Ankyra Therapeutics treated its first patient with a tumor deep within the body using ANK-101, following its strong performance treating easily accessible tumors. ANK-101 uses techniques developed in the labs of Dane Wittrup and former KI member Darrell Irvine to keep interleukin-12 anchored in tumors, enhancing immune response while reducing side effects and offering new potential for treating advanced solid tumors.